Skip to main content
SpringerLink
Log in

Pharmacokinetics of the Recombinant Thrombolytic Agents

What is the Clinical Significance of Their Different Pharmacokinetic Parameters?

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

In addition to the first generation thrombolytics streptokinase and urokinase there are now a number of new human thrombolytic proteins produced by recombinant techniques. In this review alteplase, saruplase and reteplase are discussed.

These compounds differ with respect to their pharmacokinetics. Alteplase and saruplase have relatively short half-lives and are high clearance compounds. Their clearance is dependent upon the hepatic blood flow. This is relevant as myocardial function strongly influences liver blood flow and hence the clearance of alteplase and saruplase. The clearance of reteplase is less dependent upon liver blood flow and is partly dependent on renal excretion. This extends its half-life and reteplase has been successfully administered as a double bolus injection.

The question remains if these differences are responsible for any clinical benefits that could not be accomplished by variations in dosage or dosage schedule for a single thrombolytic. Pharmacokinetic differences can only be interpreted if reasonable knowledge exists about the shape and location of the plasma concentration- (adverse) effect curves.

This information is not yet available for the recombinant thrombolytic drugs and any clinical differences could well be caused purely by differences in dosage or dosage schedule. It is recommended that plasma concentrations of thrombolytics are measured in future clinical trials, for which techniques are currently available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. European Cooperative study group for streptokinase treatment in acute myocardial infarction. Streptokinase in acute myocardial infarction. N Engl J Med 1979; 301: 797–802

    Article  Google Scholar 

  2. Kennedy JW, Ritchie JL, Davis KB, et al. The Western Washington randomised trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1985; 312: 1073–8

    Article  PubMed  CAS  Google Scholar 

  3. ISIS-3. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753–70

    Article  Google Scholar 

  4. GUSTOInvestigators. An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–82

    Article  Google Scholar 

  5. Vaughan DE, Braunwald E. Front-loaded accelerated infusions of tissue plasminogen activator: putting a better foot forward [editorial; comment]. J Am Coll Cardiol 1992; 19(5): 1076–8

    Article  PubMed  CAS  Google Scholar 

  6. Tanswell P, Tebbe U, Neuhaus KL, et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute. J Am Coll Cardiol 1992; 19(5): 1071–5

    Article  PubMed  CAS  Google Scholar 

  7. The Continuous infusion versus double-bolus administration of alteplase (COBALT) investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med 1997; 337(16): 1124–30

    Article  Google Scholar 

  8. Kluft C. Kluft C, editors. Tissue-type plasminogen activator (t-PA): physiological and clinical aspects. 1st ed. Ceveland (OH): CRC Press Inc, 1988

    Google Scholar 

  9. Noe DA, Bell WR. Akinetic analysis of fibrinogenolysis during plasminogen activator therapy. Clin Pharmacol Ther 1987; 41: 297–303

    Article  PubMed  CAS  Google Scholar 

  10. Tiefenbrunn AJ, Graor RA, Robison AK, et al. Pharmacodynamics of tissue-type plasminogen activator characterised by computer-assisted simulation. Circulation 1986; 73: 1291-9

    Google Scholar 

  11. Seifried E, Muller MM, Martin U, et al. Bolus application of a novel recombinant plasminogen activator in acute myocardial infarction. Ann N Y Acad Sci 1992; 667: 417–20

    Article  PubMed  CAS  Google Scholar 

  12. Martin U, Mollendorff Ev, Akpan W, et al. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. Clin Pharmacol Ther 1991; 50: 429–36

    Article  PubMed  CAS  Google Scholar 

  13. Martin A, Mollendorff EV, Akpan W, et al. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemostasis 1991; 66(5): 569–74

    CAS  Google Scholar 

  14. Seifried E, Tanswell P, Ellbruck D, et al. Pharmacokinetics and haemostatic status during consecutive infusions of recombinanttissue-typeplasminogen activator in patients with acute myocardial infarction. Thromb Haemost 1989; 61(3): 497–501

    PubMed  CAS  Google Scholar 

  15. Tanswell P, Seifried E, Su PC, et al. Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther 1989; 46: 155–62

    Article  PubMed  CAS  Google Scholar 

  16. Tebbe U, Tanswell P, Seifried E, et al. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 1989; 64: 448–53

    Article  PubMed  CAS  Google Scholar 

  17. Seifried E, Tanswell P, Rijken DC, et al. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Arzneimittelforschung 1988; 38: 418–22

    PubMed  CAS  Google Scholar 

  18. Koster RW, Cohen AF, Kluft C, et al. The pharmacokinetics of recombinant double chain t-PA (Duteplase): effects of bolus injection,infusions and administration by weight in patients with myocardial infarction. Clin Pharmacol Ther 1991; 50: 267–77

    Article  PubMed  CAS  Google Scholar 

  19. KosterRW, Cohen AF, Hopkins G, et al. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost 1994; 71(5): 740–4

    Google Scholar 

  20. Griensven JMTv, Burggraaf J, Gerloff J, et al. Effects of changing liver blood flow by exercise and food on kinetics and dynamics of saruplase. Clin Pharmacol Ther 1995; 57: 381–9

    Article  PubMed  Google Scholar 

  21. Cohen AF, Burggraaf J, Boer AD, et al. Clearance of plasminogen activators —a major determinant of plasma concentration. Therapeutic and diagnostic implications. Ann N Y Acad Sci 1992; 667: 443–9

    Article  PubMed  CAS  Google Scholar 

  22. Griensven JMTv, Huisman L, Stuurman T, et al. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator. Clin Pharmacol Ther 1996; 60: 504–11

    Article  PubMed  Google Scholar 

  23. Boer AD, Kluft C, Kroon JM, et al. Liver blood flow as a major determinant of the clearance of recombinant tissue-type plasminogen activator. Thromb Haemost 1992; 67: 83–7

    PubMed  Google Scholar 

  24. Griensven JMTv, Koster RW, Burggraaf J, et al. Effects of liver blood flow on the pharmacokinetics of tissue type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction. Clin Pharmacol Ther 1998: 63: 39–47

    Article  PubMed  Google Scholar 

  25. Griensven JMTV, Koster RW, Hopkins G, et al. Effect of changes in liver blood flow on the pharmacokinetics of saruplase in patients with acute myocardial infarction. Thromb Haemost 1997; 78(3): 1015–20

    PubMed  Google Scholar 

  26. Kuiper J, van de Bilt H, Martin U, et al. Uptake, internalisation and degradation of the novel plasminogen activator reteplase (BM 06.022). Thromb Haemost 1995; 74(6): 1501–10

    PubMed  CAS  Google Scholar 

  27. Martin U, Doerge L, Stegmeier K, et al. Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats. Drug Metab Dispos 1996; 24(3): 288–92

    PubMed  CAS  Google Scholar 

  28. Agnelli G, Buchanan MR, Fernandez F, et al. The thrombolytic and haemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits. Thromb Res 1985; 40: 769–77

    Article  PubMed  CAS  Google Scholar 

  29. Koster RW, Stralen van R, McNeill AJ, et al. A randomised dose-ranging study of rt-PA in acute myocardial infarction. Effects on coronary patency and fibrinolytic parameters. Eur Heart J 1990; 11: 730–9

    PubMed  CAS  Google Scholar 

  30. Collen D, Stassen JM, Larsen G. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood 1988; 71(1): 216–9

    PubMed  CAS  Google Scholar 

  31. Noble S, McTavish D. Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Drugs 1996; 52(4): 589–605

    Article  PubMed  CAS  Google Scholar 

  32. Collins R, Peto R, Baigent C, et al. Aspirin, heparin and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997; 336(12): 847–60

    Article  PubMed  CAS  Google Scholar 

  33. Chesebro JH, Knatternd GL, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142–54

    Article  PubMed  CAS  Google Scholar 

  34. Gold HK, Leinbach RC, Garabedian HD, et al. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 1986; 73: 347–52

    Article  PubMed  CAS  Google Scholar 

  35. Braunwald E, Knatternd GL, Passamani ER, et al. Announcement of protocol change in thrombolysis in myocardial infarction trial [letter]. J Am Coll Cardiol 1987; 9(2): 467

    Article  PubMed  CAS  Google Scholar 

  36. Koster RW, Cohen AF, Hopkins GR, et al. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain. Thromb Haemost 1994; 72(5): 740–4

    PubMed  CAS  Google Scholar 

  37. Collen D, Topol EJ, Tiefenbrunn AJ, et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomised, placebo-controlled trial. Circulation 1984; 70: 1012–7

    Article  PubMed  CAS  Google Scholar 

  38. Williams DO, Borer J, Braunwald E, et al. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 1986; 73: 338–46

    Article  PubMed  CAS  Google Scholar 

  39. Ware JH, Antman EM. Equivalence trials. N Engl J Med 1997; 337(16): 1159–61

    Article  PubMed  CAS  Google Scholar 

  40. Hampton JR, Schröder R, Wilcox RG. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995; 346(8971): 329–36

    Article  Google Scholar 

  41. Musselman DR, Tate DA, Oberhardt BJ, et al.Differences in clot lysis among patients demonstrated in vitro with three thrombolytic agents (tissue type plasminogen activator, streptokinase and urokinase). Am J Cardiol 1994; 73: 544–9

    Article  PubMed  CAS  Google Scholar 

  42. Schoemaker HC, Cohen AF. Estimating impossible curves using NONMEM. Br J Clin Pharmacol 1996; 42: 283–90

    Article  PubMed  CAS  Google Scholar 

  43. Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997; 95(2): 351–6 123

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leiden University Medical Centre, Centre for Human Drug Research, Leiden, The Netherlands

    Adam Cohen

  2. Zernikedreef 10, 2333CL, Leiden, The Netherlands

    Adam Cohen

Authors
  1. Adam Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adam Cohen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cohen, A. Pharmacokinetics of the Recombinant Thrombolytic Agents. BioDrugs 11, 115–123 (1999). https://doi.org/10.2165/00063030-199911020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199911020-00005

Keywords

Search

Navigation